Sanofi targets high single digit sales growth in 2026, plans share buyback

Core Viewpoint - French drugmaker Sanofi expects sales to grow by a high-single-digit percentage in 2026, driven by strong demand for its asthma drug Dupixent and newer medicines [1] Sales Growth Expectations - Sanofi anticipates a high-single-digit percentage increase in sales for the year 2026 [1] Key Products Driving Growth - The growth is primarily attributed to the strong demand for Dupixent, a blockbuster asthma drug, along with contributions from some newer medicines [1]